中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Paullinia Cupana for Anorexia in Oncologic Patients

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态
赞助商
Faculdade de Medicina do ABC

关键词

抽象

Denutrition, lost of weight and anorexia are present in many oncologic patients at any time of the disease. Anorexia is the spontaneous loss of appetite and many changes in the metabolism are made in this case, leading to this syndrome called anorexia-cachexia, that includes changes in the tumoral response and inflammatory pathways. The guaraná (Paullinia cupana) is originally from Brazil and Venezuela and has been used culturally for headaches, muscle pains, depression and others. As it has shown a good response and tolerability for fatigue, the investigators decide to try guaraná for anorexia. Patients will receive guaraná as capsules of 50 mg twice daily, for 4 weeks, and will be weighted and respond questionaries about quality of life.

描述

Patients 18 years and older, diagnosed with any cancer, that is losing weight and have anorexia will be selected. They must have normal levels of creatinine, thyroid evaluation and hepatic function. If they are taking corticosteroid, they must keep losing weight and refer anorexia, as well as if they are on treatment with chemotherapy.

Patients will receive 50mg of the guaraná twice daily for 4 weeks. Every week will be an evaluation of the weight, level of appetite and answer 2 questionaries of quality of life and level of symptoms (FACT-G and MDASI).

This is a fase II study, open-label, no randomized, with two steps following ¨two stages of Simon¨ model. First step 18 patients will be included and if there are 3 good responses second step will follow, including 17 more patients. Response will be considered if there is at least 5% of gain in the weight.

日期

最后验证: 12/31/2011
首次提交: 01/28/2012
提交的预估入学人数: 02/21/2012
首次发布: 02/27/2012
上次提交的更新: 02/21/2012
最近更新发布: 02/27/2012
实际学习开始日期: 03/31/2011
预计主要完成日期: 06/30/2013
预计完成日期: 06/30/2013

状况或疾病

Cancer-related Problem/Condition
Anorexia
Loss of Weight

干预/治疗

Drug: Paullinea cupana

相 1/相 2

手臂组

干预/治疗
Experimental: Paullinea cupana
50mg of Paullinia cupana as capsule, twice daily
Drug: Paullinea cupana
50mg of Paullinia cupana as capsule, twice daily

资格标准

有资格学习的年龄 18 Years 至 18 Years
有资格学习的性别All
接受健康志愿者
标准

Inclusion Criteria:

- adults (18 years old and older)

- palliative care or oncologic treatment

- loss of weight

- anorexia

Exclusion Criteria:

- gastrointestinal obstruction

- blood pressure not controlled

- diabetes not treated

结果

主要结果指标

1. weight [eight weeks]

Patients will considered to respond to guaraná if the gain 5% or more of his inicial weight during the treatment period

次要成果指标

1. quality of life [eight weeks]

Weekly patients will answer questionaries about quality of life like FACT-G

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge